medigraphic.com

2000, Number 1

<< Back Next >>

Rev Med Hosp Gen Mex 2000; 63 (1)

Lymphotropic human herpesviruses: Epstein-Barr (EBV), 6 y 7 (HHV-6 and HHV-7) in the pathogenia of myelodysplastic (MDS) and mieloproliferative diseases (MPS)

Rojo J, Cruz-Ortiz H, Krueger GRF

Language: Spanish
References: 42
Page: 18-24
PDF size: 608.29 Kb.


ABSTRACT

Myelodysplasic and myeloproliferative alterations have been observed in patients with lymphoproliferative diseases associated to lymphotropic human herpes viruses. Screening studies were done to eventually demonstrate the reactivation of these viruses and their possible implication in the pathogenesis and course of the myelodisplastic and myeloproliferative syndromes (MDS/MPS). We investigated 74 bone marrow biopsies and sera from patients with MDS and 49 bone marrow biopsies and 36 sera from patients with chronic myelogenous leukemia (CML), in 13 Mexican cases serologic studies were not done. Diagnosis and classification of the diseases followed the FAB (French-American-Britain) guidelines. The patients were serologically tested for antibodies (Ab) against virus capsid antigen (VCA) and the early antigen (EA) from the EBV (ELISA and IFA-immunofluorescence) and HHV-6 and HHV-7 (IFA). The immunohistology was done by the APAAP technique and with the monoclonal Ab against the proliferation cell nuclear antigen (PCNA). IgG titers anti-EBV-EA were found in 62% of the cases of MDS and in 33% with CML, IgG titers against HHV-6 were elevated in 19% of the cases with MDS and in 9.3% with CML, HHV-7 was found in 37.8% and 13.9% respectively. IgM titers were negative for the 3 viruses. The EBV-EA expression was positive in the bone marrow in 76% of the MDS cases, 48.6% were positive to HHV-6 p41 and 37.8% were positive to HHV-7. The CML cases expressed EBV-EA in 77%, HHV-6 in 54.5% and HHV-7 in 21.8%.


REFERENCES

  1. Levine PH, Jarret R, Lark DA. The epidemiology of human herpes virus-6. In: Ablashi DV, Krueger GRF, Salahuddin SZ. Human herpesvirus-6. Epidemiology, molecular biology and clinical pathology. Amsterdam: Elsevier Science Publishers, 1992: 9-23.

  2. Krueger GRF, Sander C. What’s new in human herpesvirus-6? Clinical immunopathology of the HHV-6 infection. Path Res Pract 1989; 185: 915-929.

  3. Purtilo DT, Tatsumi E, Manolov G, Manolova Y, Harada S, Lipscomb H et al. Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients. Int Rev Pathol 1985; 27: 113-183.

  4. Salahuddin SZ, Kelley AS, Krueger GRF, Josephs SF, Gupta S, Ablashi DV. Human herpesvirus-6 (HHV-6) in diseases. Clin Diagn Virol 1993; 1: 81-100.

  5. Rojo J, Ferrer Argote V, Klueppelberg U, Krueger GRF, Eidt S, Ablashi DV et al. Semiquantitative in situ hybridization and immunohistology for antigen expression of human herpesvirus-6 in various lymphoproliferative diseases. In Vivo 1994; 8: 517-526.

  6. Krueger GRF, Ablashi DV, Gallo RC. Persistent herpesvirus infections. Current techniques for diagnosis. J Virol Methods 1988; 21: 1-326

  7. Krueger GRF, Klueppelberg U, Hoffmann A, Ablashi DV. Clinical correlates of the infection with human herpesvirus-6. In vivo 1994; 8: 457-486

  8. Schonnebeck M, Krueger GRF, Braun M, Fischer M, Joch B, Ablashi DV et al. Human herpesvirus-6 infection may predispose cells to superinfection by other viruses. In vivo 1991; 5: 255-264.

  9. Harada S, Tatsumi E, Lipscomb H, Purtilo DT. Responses to Epstein-Barr virus in immune deficient patients. In: Purtilo DT: Immune deficiency and cancer. New York: Plenum Med Book, 1984: 123-141.

  10. Krueger GRF, Ablashi DV, Ramon A, Lembke U. Frequency and pathogenic implication of reactivated lymphotropic herpesviruses in autoimmune and immune deficiency disorders. In: Imbach P: Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991: 174-192.

  11. Krueger GRF, Sander C, Hoffmann A, Barth A, Koch B, Braun M. Isolation of human herpesvirus-6 (HHV-6) from patients with collagen vascular disease. In vivo 1991; 5: 217-226.

  12. Krueger GRF, Ablashi DV, Lusso P, Josephs SF. Immunological dysregulation of lymph nodes in AIDS patients. Curr Topics Path 1991; 82/2: 157-188.

  13. McKhan II G, Gibbs Jr CJ, Mora CA, Rodgers-Johnson PE, Liberski PP, Gdula WJ et al. Isolation and characterization of HTLV-1 from symptomatic family members with tropical spastic paraparesis (HTLV-1 encephalomyeloneuropathy). J Infect Dis 1989; 160: 371-379.

  14. Berman A, Espinoza LR, Díaz JD, Aguilar JL, Rolando T, Vasay FB et al. Rheumatic manifestations of human immunodeficiency virus infection. Amer J Med 1988; 85: 59-64.

  15. Komaroff AL, Gupta S, Salit IE. Post viral chronic fatigue syndrome. In: Ablashi DV, Krueger GRF, Salahuddin SZ: Human herpesvirus-6: epidemiology, molecular biology and clinical pathology. Amsterdam: Elsevier Science Publisher, 1992: 235-253.

  16. Fox R. Epstein-Barr virus and autoimmune disease: possibilities and pitfalls. J Virol Methods 1988; 21: 19-27.

  17. Krueger GRF, Guenther A, Knuefermann R, Klueppelberg U, Luka J, Pearson GR et al. Human herpesvirus-6 (HHV-6) in Hodgkin’s disease: cellular expression of viral antigens as compared to the suppressor gene product p53, and the interleukins 2 and 6. In vivo. 1994; 8: 501-516.

  18. Fohlmeister Y, Fischer R, Schaefer HE. Preleukemic myelodisplastic syndromes (MDS): Pathogenetical considerations based on retrospective clinico morphologic sequential studies. Anticancer Res 1985; 5: 179-188.

  19. Krueger GRF, Kudlimay D, Ramon A, Klueppelberg U, Schumacher K. Demonstration active and latent Epstein-Barr virus and human herpesvirus-6 infections in bone marrow cells of patients with myelodysplasia and chronic myeloproliferative diseases. In vivo. 1994; 8: 533-542.

  20. Krueger GRF, Manak M, Bourgeois N, Ablashi DV, Salahuddin SZ, Josephs SF et al. Persistent active herpes virus infection associated with atypical polyclonal lymphoproliferation (APL) and malignant lymphoma. Anticancer Res 1989; 9: 1457-1476.

  21. Krueger GRF, Ostmeier H, Koch B, Seyda M, Ramon A, Raftery B et al. Lymphatic response to persistent active virus infections in immune deficiency. In: Levine PH (ed). Epstein-Barr virus and human disease. Clifton, NJ: Humana Press, 1987: 361-366.

  22. Krueger GRF, Guenther A, Knuefermann R, Klueppelberg U, Luka J, Pearson GR et al. Human herpesvirus-6 (HHV-6) in Hodgkin’s Disease: Cellular expression of viral antigens as compared to the oncogens Met and Fes, the tumor suppressor gene product p53 and the interleukins 2 and 6. In vivo 1994; 8: 501-516.

  23. Krueger GRF, Ablashi DV, Salahuddin SZ, Josephs SF. Diagnosis and differential diagnosis of progressive lymphoproliferation and Malignant Lymphoma in persistent active herpesvirus infection. J Virol Methods 1988; 21: 125-131.

  24. Krueger GRF. Abnormal variation of immune system as related to cancer. In: Kaiser HE (ed). Cancer growth and progression. Dordrecht NL: Kluwer Acad Publ, 1989; 4: 139-162.

  25. Delacretaz F, Schmidt PM, Piguet D, Bachman F, Costa J. Histopathology of myelodisplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Path 1987; 87: 180-186.

  26. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick H et al. Proposals for the classification of myelodisplastic syndromes. Brit J Haematol 1982; 51: 189-199.

  27. Georgii A, Vykoupil KF, Buhr T, Choritz H, Doehler U, Kaloutsi V et al. Chronic myeloproliferative disorders in bone marrow biopsies. Path Res Pract 1990; 186: 3-27.

  28. Vardiman JW. Chronic Myelogenous leukemia and the myeloproliferative disorders. In: Knowles DM. Neoplastic hematopathology. Baltimore: William & Wilkins, 1992: 1405-1438.

  29. Cordell JL, Falini B, Erber WN, Gosh AK, Abdulaziz Z, MacDonald S et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32 (2): 219-229.

  30. Krueger GRF, Sievert J, Juecker M, Tesch H, Diel V, Ablashi DV et al. Hodgkin’s cells express human herpesvirus-6 antigens. J Viral Dis 1992; 1: 15-23.

  31. Cuoma L, Angeloni A, Zompetta C, Cirone M, Calogero A, Frati L et al. Human herpesvirus-6 variant A, but not variant B, infects EBV-positive B lymphoid cells, activating the latent EBV genome through a BZLF-1-dependent mechanism. AIDS Res Hum Retroviruses 1995; 11 (10): 1241-1245.

  32. Valente G, Secchiero P, Lusso P, Abete MC, Jemma C, Reato G et al. Human herpesvirus-6 and Epstein-Barr virus in Hodgkin’s disease: a controlled study by polymerase chain reaction and in situ hybridization. Am J Pathol 1996; 149 (5): 1501-1510.

  33. Alexander FE, Daniel CP, Armstrong AA, Clark DA, Onions DE, Cartwright RA et al. Case clustering, Epstein-Barr virus Reed-Sternberg cells status and herpes virus serology in Hodgkin’s disease: Results of a case control study. Eur J Cancer 1995; 31 A (9): 1479-1486.

  34. Trovato R, Di Lollo S, Calzolari A, Torelli G, Ceccherini-Nelli L. Detection of human herpesvirus-6 and Epstein-Barr virus genome in childhood Hodgkin’s disease. Pathologica 1994; 86 (5): 500-503.

  35. Razzaque A, Francillon Y, Jilly PN, Varicchio F. Detection of human herpesvirus-6 sequences in lymphoma tissues by immunohistochemistry and polymerase chain reactions. Cancer Lett 1996; 106 (2): 221-226.

  36. Rojo J, Krueger GRF, Leyssens N. Linfoproliferación atípica policlonal en cavidad peritoneal en un paciente con SIDA y con infección por virus de Epstein-Barr, humano herpes-6 y humano herpes-8. Rev Med Hosp Gen Mex 1997; 60 (3): 140-146.

  37. Dolcetti R, Di Luca D, Carbone A, Mirandola P, De Vita S, Vaccher E et al. Human herpesvirus-6 in human immunodeficiency virus-infected individuals: association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders. J Med Virol 1996; 48 (4): 344-353.

  38. Knox KK, Carrigan DR. Active HHV-6 infection in the lymph nodes HIV-infected patients: in vitro evidence that HHV-6 can break HIV latency. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11 (4): 370-378.

  39. Zoechbauer S, Gsur A, Goetzl M, Wallner J, Lechner K, Pirker R. MDR1 Gene expression in myelodysplastic syndrome and in acute myeloid leukemia evolving from myelodysplastic syndrome. Anticancer Res 1994; 14: 1293-1296.

  40. Kitagawa M, Yoshida SH, Kuwata T, Tanizawa T, Kamiyama R. P53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. Am J Pathol 1994; 145: 338-344.

  41. Klussmann JP, Krueger E, Sloots T, Berneman Z, Arnold G, Krueger GRF. Ultrastructural study of human herpesvirus-7 replication in tissue culture. Virchows Arch 1997; 430: 417-426.

  42. Kirn E, Krueger E, Boehmer S, Klussmann JP, Krueger GRF. In vitro cytobiological effects of human herpesviruses 6 and 7: Immunohistological monitoring of apoptosis, differentiation and cell proliferation. Anticancer Res 1997; 17: 4623-4632.




2020     |     www.medigraphic.com